CN102153534B - 具酪氨酸酶抑制活性的化合物及制备方法与用途 - Google Patents
具酪氨酸酶抑制活性的化合物及制备方法与用途 Download PDFInfo
- Publication number
- CN102153534B CN102153534B CN 201110059065 CN201110059065A CN102153534B CN 102153534 B CN102153534 B CN 102153534B CN 201110059065 CN201110059065 CN 201110059065 CN 201110059065 A CN201110059065 A CN 201110059065A CN 102153534 B CN102153534 B CN 102153534B
- Authority
- CN
- China
- Prior art keywords
- ethyl acetate
- compound
- glucopyranoside
- preparation
- tyrosinase inhibitory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 102000003425 Tyrosinase Human genes 0.000 title claims abstract description 21
- 108060008724 Tyrosinase Proteins 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 18
- 240000000249 Morus alba Species 0.000 claims abstract description 21
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000004262 preparative liquid chromatography Methods 0.000 claims abstract description 18
- 239000003480 eluent Substances 0.000 claims abstract description 17
- 238000001035 drying Methods 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 10
- 239000000741 silica gel Substances 0.000 claims abstract description 10
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 84
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 17
- 230000006837 decompression Effects 0.000 claims description 14
- 238000011084 recovery Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 238000000926 separation method Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 238000004237 preparative chromatography Methods 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 6
- HVGQWHMSVYODLJ-GFCCVEGCSA-N melanochrome Natural products CC1(C)Oc2cc3OC(=CC(=O)c3c(O)c2C[C@H]1O)CO HVGQWHMSVYODLJ-GFCCVEGCSA-N 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 230000019612 pigmentation Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- -1 polyphenol compounds Chemical class 0.000 abstract description 8
- 239000000243 solution Substances 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract 4
- 235000013824 polyphenols Nutrition 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 230000008099 melanin synthesis Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 23
- CHAAQDMHLLQJRO-UHFFFAOYSA-N Moracin D Chemical compound C1=C(O)C=C2OC(C=3C=C4OC(C=CC4=C(O)C=3)(C)C)=CC2=C1 CHAAQDMHLLQJRO-UHFFFAOYSA-N 0.000 description 19
- JJOUBYOHNYJCOU-IBGZPJMESA-N (2s)-2-(2,4-dihydroxyphenyl)-7-hydroxy-8-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one Chemical compound C1([C@@H]2CC(=O)C=3C=CC(O)=C(C=3O2)CC=C(C)C)=CC=C(O)C=C1O JJOUBYOHNYJCOU-IBGZPJMESA-N 0.000 description 17
- 239000003921 oil Substances 0.000 description 15
- JJOUBYOHNYJCOU-UHFFFAOYSA-N Euchrenone a7 Natural products O1C=2C(CC=C(C)C)=C(O)C=CC=2C(=O)CC1C1=CC=C(O)C=C1O JJOUBYOHNYJCOU-UHFFFAOYSA-N 0.000 description 12
- 229930182512 Moracin Natural products 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 8
- 238000010828 elution Methods 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 239000006187 pill Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000001142 circular dichroism spectrum Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011137 process chromatography Methods 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- IEWSZUNUKKOVGR-UHFFFAOYSA-N 2-(3,5-dihydroxyphenyl)benzofuran-6-yl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=C(O2)C=3C=C(O)C=C(O)C=3)C2=C1 IEWSZUNUKKOVGR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229940124200 Melanin inhibitor Drugs 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明提供一类具有酪氨酸酶抑制活性的化合物,包括六种从桑叶中提取的具有酪氨酸酶抑制活性的多酚类化合物。将药材经乙醇水溶液加热提取,浓缩,硅胶柱分离,洗脱,洗脱液浓缩干燥,再用制备液相色谱继续分离,收集溶液,溶液浓缩干燥后得到样品并进行结构鉴定。本发明还提供了从桑叶中分离上述多酚类化合物的方法。本发明提供的六种多酚类化合物具有较强的酪氨酸酶抑制活性,能够有效预防和治疗黑色素合成异常导致的人体色素沉着性疾病、黑色素瘤以及其它需要抑制酪氨酸酶活性的病症,可用于制备治疗此类疾病的药物。
Description
技术领域
本发明属于中药领域,具体地说涉及从中药桑叶中提取的具有酪氨酸酶抑制活性的化合物及其制备方法和制药用途。
背景技术
桑叶,又名“铁扇子”,属于桑科桑属植物桑(Morus alba L.)。桑叶作为药用始载于《神农本草经》,其味苦、性寒,具有补血、疏风、散热、益肝通气、降压利尿等功效。现代大量的药理学研究证明了桑叶具有降血糖、降血压、降血脂、清除自由基、抗衰老、抗炎、抗菌、抗病毒和抗癌等诸多药理作用。桑叶化学成分有黄酮、甾体、香豆素、挥发油、生物碱、氨基酸、有机酸、维生素和多糖等。
酪氨酸酶作为黑色素合成的关键酶,其异常过量表达可导致人体的色素沉着性疾病及黑色素瘤等。因此,酪氨酸酶抑制剂可作为黑色素抑制剂应用于医药等领域。
发明内容
本发明的目的在于提供一类具有酪氨酸酶抑制活性的化合物,是从桑叶中提取的具有酪氨酸酶抑制活性的六种多酚类化合物,包括 (2S)-Euchrenone a7,桑辛素M-6-β-D-吡喃葡萄糖苷[Moracin M 6-(β-D-glucopyranoside)] ,(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷[(2S)-7-hydroxyl-8-hydroxyethyl-4'-methoxylflavane-2'-O-β-D-glucopyranoside],(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷[(2S)-7-methoxyl-8-hydroxyethyl-4'-hydroxylflavane-2'-O-β-D-glucopyranoside],(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷[(2S)-8-hydroxyethyl-7, 4'-dimethoxylflavane-2'-O-β-D-glucopyranoside],桑辛素D(Moracin D),其结构如下:
本发明的另一个目的是提供所述具有酪氨酸酶抑制活性的化合物的制备方法,通过以下步骤实现:
(1)将桑叶用70%乙醇回流提取,提取物减压浓缩至浸膏;
(2)将浸膏混悬于适量水中,用石油醚脱脂,乙酸乙酯萃取;
(3)将乙酸乙酯萃取部分浓缩至浸膏,用正相硅胶分离,洗脱剂为体积比为100:0~ 90:10的石油醚和乙酸乙酯;体积比为82:18的石油醚和乙酸乙酯;体积比为78:22~65:35的石油醚和乙酸乙酯;体积比为60:40的石油醚和乙酸乙酯及乙酸乙酯;
(4)分别收集体积比为82:18的石油醚和乙酸乙酯洗脱液、体积比为60:40的石油醚和乙酸乙酯洗脱液及乙酸乙酯洗脱液浓缩干燥后得样品,用制备液相色谱继续分离得到的化合物;制备色谱的分离条件:色谱柱为制备柱,流动相为水和甲醇,梯度洗脱。
步骤(4)收集体积比为60:40的石油醚和乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品,制备色谱的分离条件:色谱柱为制备柱Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,30%B;20 min,50%B;27 min,50%B;28 min,60%B;35 min,60%B;36 min,70%B;50 min,70%B;60 min,80%B;流速:10ml/min,检测波长:210nm,收集48.5 min的色谱峰,减压回收溶剂,即得(2S)-Euchrenone a7化合物。
步骤(4)收集体积比为82:18的石油醚和乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件: 色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,5%B;5 min,30%B;27 min,30%B;40 min,35%B;41 min,67%B;65 min,67%B;80 min,80%B;流速:10ml/min,检测波长:210nm,收集72.5min的色谱峰,减压回收溶剂,即得桑辛素D化合物。
步骤(4)收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件: 色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B;流速:10ml/min,检测波长:210nm,收集31.9min的色谱峰,减压回收溶剂,即得桑辛素M-6-β-D-吡喃葡萄糖苷化合物。
步骤(4)收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件:色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B,流速:10ml/min,检测波长:210nm;收集58.0 min的色谱峰,减压回收溶剂,即得(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷化合物。
步骤(4)收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件: 色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B;流速:10ml/min,检测波长:210nm。收集64.7 min的色谱峰,减压回收溶剂,即得(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷化合物。
步骤(4)收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件: 色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B;流速:10ml/min,检测波长:210nm,收集76.6 min的色谱峰,减压回收溶剂,即得(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷化合物。
本发明的另一个目的是提供所述的具有酪氨酸酶抑制活性的化合物在制备预防和治疗黑色素合成异常导致的人体色素沉着性疾病、黑色素瘤以及其它需要抑制酪氨酸酶活性的病症的药物中的应用。
本发明的六种桑叶中提取的具有酪氨酸酶抑制活性的多酚类化合物可以作为活性成分,加入药剂学上接受的辅料,按照药剂学上记载的制剂的制备方法制成制剂。
所述的制剂包括注射液、滴注液、粉针剂、颗粒剂、片剂、冲剂、散剂、口服液、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口含剂、颗粒剂、丸剂、膏剂、丹剂、喷雾剂、滴丸剂 、崩解剂、口崩片、微丸等。
本发明的有益之处是:提供的六种桑叶中提取的具有酪氨酸酶抑制活性的多酚类化合物具有比桑叶提取物更强的活性,制成制剂易于药物的质量控制,可在制备预防和治疗黑色素合成异常导致的人体色素沉着性疾病、黑色素瘤以及其它需要抑制酪氨酸酶活性的病症中应用。
具体实施方式
下面将结合实施例进一步详细说明本发明的实质内容和有益效果,该实施例仅用于说明本发明而非对本发明的限制。
实施例一 (2S)-Euchrenone a7的制备
将10 kg桑叶用9倍量70%乙醇回流提取2次,每次2h,减压浓缩至浸膏,取浸膏混悬于适量水中,用石油醚萃取脱脂,分离水层再用乙酸乙酯萃取6次。将乙酸乙酯萃取部分减压回收溶剂,得160 g浸膏,将浸膏与100-200目硅胶按重量比为1:1的比例拌匀后,加于硅胶柱中分离。洗脱剂为体积比为100:0~ 90:10的石油醚和乙酸乙酯;体积比为82:18的石油醚和乙酸乙酯;体积比为78:22~65:35的石油醚和乙酸乙酯;体积比为60:40的石油醚和乙酸乙酯及乙酸乙酯,收集体积比为60:40的石油醚和乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件:色谱柱为制备柱,流动相为水和甲醇,梯度洗脱。
制备液相色谱分离条件:
仪器:岛津 LC-8A 制备液相色谱仪配以DAD检测器。
色谱柱:Agilent Zorbax SB-C18柱 (250×21.2 mm, 7 μm)。
流动相:A相:水;B相:甲醇。线性洗脱梯度:0 min,30%B;20 min,50%B;27 min,50%B;28 min,60%B;35 min,60%B;36 min,70%B;50 min,70%B;60 min,80%B。流速:10ml/min,检测波长:210nm。收集48.5min的色谱峰,减压回收溶剂,得(2S)-Euchrenone a7。
(2S)-Euchrenone a7的核磁共振光谱及质谱数据如下:
1H NMR (500MHz, DMSO-d6): δ 7.50 (1H, d, H-5), 7.21 (1H, d, H-6'), 6.55 (1H, d, H-6), 6.34 (1H, d, H-3'), 6.25 (1H, dd, H-5'), 5.23 (1H, dd, H-2), 5.15 (1H, dd, H-2''), 3.18 (1H, d, H-1''), 3.00, 2.58 (2H, 2m, H-4), 1.58 (6H, s, CH3-4', 5')。13C NMR (500MHz, DMSO-d6): δ 74.4 (C-2), 42.4 (C-3), 191.1 (C-4), 113.4 (C-4a), 125.3 (C-5), 109.7 (C-6), 162.1 (C-7), 114.9 (C-8), 161.2 (C-8a), 116.3 (C-1'), 155.6 (C-2'), 102.4 (C-3'), 158.3 (C-4'), 106.3 (C-5'), 126.7 (C-6'), 21.8 (C-1''), 122.4 (C-2''), 130.5 (C-3''),17.7 (C-4''), 25.5 (C-5'')。
ESI-MS: m/z 339.19 [M-H]-。
CD谱中,在275nm处的Cotton效应为Δε =-0.0345。
结构解析表明该化合物为:(2S)-Euchrenone a7。
实施例二 桑辛素D的制备
桑叶的提取、萃取、硅胶柱分离过程同实施例一。所不同的是收集体积比为82:18的石油醚和乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件:色谱柱为制备柱,流动相为水和甲醇,梯度洗脱。
制备液相色谱条件:
仪器:岛津 LC-8A 制备液相色谱仪配以DAD检测器。
色谱柱:Agilent Zorbax SB-C18柱 (250×21.2 mm, 7 μm)。
流动相:A相:水;B相:甲醇。线性洗脱梯度:0 min,5%B;5 min,30%B;27 min,30%B;40 min,35%B;41 min,67%B;65 min,67%B;80 min,80%B。流速:10ml/min,检测波长:210nm。收集72.5min的色谱峰,减压回收溶剂,得桑辛素D。
桑辛素D的核磁共振光谱及质谱数据如下:1H NMR (500MHz, DMSO-d6): δ 7.37 (1H, d, H-4), 7.15 (1H, s, H-3), 6.93 (1H, d, H-7), 6.86 (1H, d, H-2'), 6.74 (1H, dd, H-5), 6.72 (2H, d, H-6'), 6.58 (1H, d, H-7'), 5.66 (1H, d, H-8'),1.37 (6H, s, CH3-10', 11')。13C NMR (500MHz, DMSO-d6): δ 153.9 (C-2), 102.4 (C-3), 121.2 (C-3a), 121.6 (C-4), 113.1 (C-5), 156.4 (C-6), 97.9 (C-7), 155.8 (C-7a), 130.9 (C-1'), 103.9 (C-2'), 154.1 (C-3', 5'), 109.6 (C-4'), 103.4 (C-6'), 117.1 (C-7'), 129.2 (C-8'), 76.1 (C-9'), 27.9 (C-10', 11')。
ESI-MS: m/z 307.30 [M-H]-。
结构解析表明该化合物为:桑辛素D。
实施例三 桑辛素M-6-β-D-吡喃葡萄糖苷的制备
桑叶的提取、萃取、硅胶柱分离过程同实施例一。所不同的是收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件:色谱柱为制备柱,流动相为水和甲醇,梯度洗脱。
制备液相色谱条件:
仪器:岛津 LC-8A 制备液相色谱仪配以DAD检测器。
色谱柱:Agilent Zorbax SB-C18柱 (250×21.2 mm, 7 μm)。
流动相:A相:水;B相:甲醇。线性洗脱梯度:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B。流速:10ml/min,检测波长:210nm。收集31.9min的色谱峰,减压回收溶剂,得桑辛素M-6-β-D-吡喃葡萄糖苷。
桑辛素M-6-β-D-吡喃葡萄糖苷的核磁共振光谱及质谱数据如下:
1H NMR (500MHz, DMSO-d6): δ 7.51 (1H, d, H-4), 7.32 (1H, d, H-7), 7.17 (1H, s, H-3), 6.97 (1H, dd, H-5), 6.73 (2H, d, H-2', 6'), 6.25 (1H, d, H-4'), 4.92 (1H, d, H-1''), 3.74, 3.48 (2H, 2m, H-6''), 3.40 (1H, m, H-5''), 3.29 (H, m, H-3''), 3.28 (H, m, H-2''), 3.18 (H, m, H-4'')。13C NMR (500MHz, DMSO-d6): δ 155.0 (C-2), 101.7 (C-3), 123.5 (C-3a), 121.3 (C-4), 113.9 (C-5), 155.9 (C-6), 99.4 (C-7), 155.4 (C-7a), 131.9 (C-1'), 102.8 (C-2', 6'), 159.1 (C-3', 5'), 103.3 (C-4'), 101.5 (C-1''), 73.6 (C-2''), 76.9 (C-3''), 70.0 (C-4''), 77.4 (C-5''), 61.1 (C-6'')。
ESI-MS: m/z 449.19 [M+HCOO]-, 403.12 [M-H]-。
结构解析表明该化合物为:桑辛素M-6-β-D-吡喃葡萄糖苷。
实施例四 (2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷的制备
桑叶的提取、萃取、硅胶分离过程以及制备液相色谱条件如实施例三,所不同的是收集58.0 min的色谱峰,减压回收溶剂,得(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷。
(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷的核磁共振光谱及质谱数据如下:
1H NMR (500MHz, DMSO-d6): δ 7.28 (1H, d, H-6'), 6.78 (1H, d, H-3'), 6.72 (1H, d, H-5), 6.64 (1H, dd, H-5'), 6.36 (1H, d, H-6), 5.47 (1H, dd, H-2), 4.81 (1H, d, H-1'''), 3.74 (3H, s, OCH3-4'), 3.76, 3.52 (2H, 2m, H-6'''), 3.49 (H, m, H-2''), 3.39 (2H, m, 5'''), 3.29 (H, m, H-2''', 3'''), 3.18 (H, m, H-4'''), 2.77 (H, m, H-1''), 2.54, 2.82 (2H, 2m, H-4), 2.09, 1.69 (2H, 2m, H-3)。13C NMR (500MHz, DMSO-d6): δ 71.8 (C-2), 29.1 (C-3), 24.3 (C-4), 112.7 (C-4a), 127.2 (C-5), 107.6 (C-6), 154.6 (C-7), 112.2 (C-8), 153.9 (C-8a), 123.9 (C-1'), 154.9 (C-2'), 102.1 (C-3'), 159.7 (C-4'), 107.5 (C-5'), 126.6 (C-6'), 27.2 (C-1''), 60.5 (C-2''), 55.4 (OCH3-4'), 101.8 (C-1'''), 73.6 (C-2'''), 76.8 (C-3'''), 70.2 (C-4'''), 77.4 (C-5'''), 61.1 (C-6''')。
ESI-MS: m/z 477.02 [M-H]-。
CD谱中,在275nm处的Cotton效应为Δε =-1.026。
结构解析表明该化合物为:(2S)-7-羟基-8--羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷。
实施例五 (2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷的制备
桑叶的提取、萃取、硅胶分离过程以及制备液相色谱条件如实施例三,所不同的是收集64.7min的色谱峰,减压回收溶剂,得(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷。
(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷的核磁共振光谱及质谱数据如下:
1H NMR (500MHz, DMSO-d6): δ 7.14 (1H, d, H-6'), 6.88 (1H, d, H-5), 6.61 (1H, d, H-3'), 6.49 (2H, m, H-6, 5'), 5.47 (1H, dd, H-2), 4.73 (1H, d, H-1'''), 3.73 (3H, s, OCH3-7), 3.74, 3.53 (2H, 2m, H-6'''), 3.43 (H, m, H-2''), 3.29 (2H, m, H-5'''),3.26 (2H, m, H-3'''), 3.25 (H, m, H-2'''), 3.22 (H, m, H-4'''), 2.76 (H, m, H-1''), 2.59, 2.86 (2H, 2m, H-4), 2.10, 1.70 (2H, 2m, H-3)。13C NMR (500MHz, DMSO-d6): δ 72.0 (C-2), 28.9 (C-3), 24.2 (C-4), 114.6 (C-4a), 127.2 (C-5), 109.1 (C-6), 156.5 (C-7), 113.3 (C-8), 153.7 (C-8a), 122.0 (C-1'), 154.9 (C-2'), 103.1 (C-3'), 157.8 (C-4'), 103.0 (C-5'), 126.4 (C-6'), 27.0 (C-1''), 60.1 (C-2''), 55.7 (OCH3-7), 101.8 (C-1'''), 73.5 (C-2'''), 76.6 (C-3'''), 69.7 (C-4'''), 77.1 (C-5'''), 60.8 (C-6''')。
ESI-MS: m/z 477.27 [M-H]-。
CD谱中,在275nm处的Cotton效应为Δε =-0.731。
结构解析表明该化合物为:(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷。
实施例六 (2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷的制备
桑叶的提取、萃取、硅胶分离过程以及制备液相色谱条件如实施例三,所不同的是收集76.6min的色谱峰,减压回收溶剂,得(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷。
(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷的核磁共振光谱及质谱数据如下:
1H NMR (500MHz, DMSO-d6): δ 7.24 (1H, d, H-6'), 6.89 (1H, d, H- H-5), 6.77 (1H, d, H-3'), 6.63 (1H, dd, H-5'), 6.50 (1H, d, H-6), 5.49 (1H, dd, H-2), 4.78 (1H, d, H-1'''), 3.74 (3H, s, OCH3-4'), 3.73 (3H, s, OCH3-7), 3.73, 3.45 (2H, 2m, H-6'''), 3.36 (2H, m, H-2'', 5'''), 3.27 (H, m, H-3'''), 3.25 (H, m, H-2'''), 3.14 (H, m, H-4'''), 2.75 (H, m, H-1''), 2.58, 2.86 (2H, 2m, H-4), 2.09, 1.69 (2H, 2m, H-3)。13C NMR (500MHz, DMSO-d6): δ 71.7 (C-2), 28.7 (C-3), 24.0 (C-4), 114.5 (C-4a), 127.1 (C-5), 103.1 (C-6), 156.4 (C-7), 113.2 (C-8), 153.5 (C-8a), 123.4 (C-1'), 154.7 (C-2'), 101.8 (C-3'), 159.5 (C-4'), 107.3 (C-5'), 126.2 (C-6'), 27.0 (C-1''), 60.0 (C-2''), 55.1 (OCH3-7), 55.6 (OCH3-4'), 101.6 (C-1''), 73.3 (C-2''), 76.5 (C-3''), 69.9 (C-4''), 77.2 (C-5''), 60.9 (C-6'')。
ESI-MS: m/z 491.72 [M-H]-。
CD谱中,在275nm处的Cotton效应为Δε =-1.060。
结构解析表明该化合物为:(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷。
实施例七 酪氨酸酶抑制活性的评价
将桑叶总提物配成6.25,12.5,25,50,100μg/ml浓度的溶液;将(2S)-Euchrenone a7,桑辛素D,桑辛素M-6-β-D-吡喃葡萄糖苷,(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷,(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷及(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷分别配成3.125,6.25,12.5,25,50 μmol/L浓度的溶液;将阳性药物曲酸配成6.25,12.5,25,50,100 μmol/L浓度的溶液。取96孔板,加250U/ml 酪氨酸酶20μl,各浓度待测样品溶液20μl,及100μl磷酸盐缓冲液(100 mmol/L,pH 6.8)混匀后25 °C下孵育10min。再加反应底物3 mmol/L L-酪氨酸20μl,混匀后25 °C下孵育30min。在492nm处测定其吸光度值。其中酶溶液,样品溶液,反应底物溶液均以100 mmol/L,pH 6.8磷酸盐缓冲液配制。
酶活性抑制率=[A空白-( A样品-A背景)]/ A空白×100%
A空白:含底物和酶,不加待测样品反应后的吸收值;
A样品:含底物和酶,加入待测样品反应后的吸收值;
A背景:含底物和待测样品,不加酶的吸收值。
桑叶总提物的IC50值为68.04 μg/ml,(2S)-Euchrenone a7,桑辛素D,桑辛素M-6-β-D-吡喃葡萄糖苷,(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷,(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷,(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷的IC50值分别为0.31 μmol/L (0.11μg/ml),16.67 μmol/L (5.13μg/ml),29.26 μmol/L (11.82μg/ml),24.02 μmol/L (11.48 μg/ml),11.32 μmol/L (5.41μg/ml)和20.72 μmol/L (10.19μg/ml),阳性药物曲酸的IC50值为17.29 μmol/L (2.46μg/ml)。
实施例八 滴丸制剂的制备
取具有酪氨酸酶抑制活性的(2S)-Euchrenone a7或桑辛素D或桑辛素M-6-β-D-吡喃葡萄糖苷或(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷或(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷或(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷0.1g与10.5g聚乙二醇-20000混合均匀,加热熔融,化料后移至滴丸滴灌中,药液滴至6~8℃液体石蜡中,除油,制得滴丸400粒。
实施例十一 冻干粉针剂的制备
取具有酪氨酸酶抑制活性的(2S)-Euchrenone a7或桑辛素D或桑辛素M-6-β-D-吡喃葡萄糖苷或(2S)-7-羟基-8-羟乙基-4'-甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷或(2S)-7-甲氧基-8-羟乙基-4'-羟基黄烷-2'-O-β-D-吡喃葡萄糖苷或(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷0.1g、葡萄糖4.5g、硫代硫酸钠0.9g和蒸馏水1000ml,上述组分混合均匀后,分装400支,冷冻干燥,即得。
Claims (4)
1.一种具有酪氨酸酶抑制活性的化合物,其特征在于,所述化合物为:(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷。
2.根据权利要求1所述的一种具有酪氨酸酶抑制活性的化合物的制备方法,其特征在于, 通过以下步骤实现:(1)将桑叶用70%乙醇溶液回流提取,提取物减压浓缩至浸膏;(2)将浸膏混悬于适量水中,用石油醚脱脂,乙酸乙酯萃取;(3)将乙酸乙酯萃取部分用正相硅胶分离,洗脱剂为体积比为100:0~ 90:10的石油醚和乙酸乙酯,体积比为82:18的石油醚和乙酸乙酯,体积比为78:22~65:35的石油醚和乙酸乙酯,体积比为60:40的石油醚和乙酸乙酯及乙酸乙酯;(4)收集乙酸乙酯洗脱液,浓缩干燥后得样品,用制备液相色谱继续分离得到的样品;制备色谱的分离条件:色谱柱:Agilent Zorbax SB-C18柱 250×21.2 mm, 7 μm,流动相为水A和甲醇B,梯度洗脱程序如下:0 min,25%B;32 min,44%B;47 min,44%B;48 min,55%B;71 min,60%B;75 min,100%B;流速:10ml/min,检测波长:210nm,收集76.6 min的色谱峰,减压回收溶剂,即得。
3.根据权利要求1所述的一种具有酪氨酸酶抑制活性的化合物在制备预防和治疗黑色素合成异常导致的人体色素沉着性疾病、黑色素瘤以及其它需要抑制酪氨酸酶活性的病症药物中的应用。
4.根据权利要求3所述的应用,其特征在于,所述药物由(2S)-8-羟乙基-7, 4'-二甲氧基黄烷-2'-O-β-D-吡喃葡萄糖苷加入药剂学上可接受的辅料,按照药剂学上记载的制剂制备方法制成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110059065 CN102153534B (zh) | 2011-03-13 | 2011-03-13 | 具酪氨酸酶抑制活性的化合物及制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110059065 CN102153534B (zh) | 2011-03-13 | 2011-03-13 | 具酪氨酸酶抑制活性的化合物及制备方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102153534A CN102153534A (zh) | 2011-08-17 |
CN102153534B true CN102153534B (zh) | 2013-03-13 |
Family
ID=44435249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110059065 Expired - Fee Related CN102153534B (zh) | 2011-03-13 | 2011-03-13 | 具酪氨酸酶抑制活性的化合物及制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102153534B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102660630A (zh) * | 2011-12-19 | 2012-09-12 | 上海相宜本草化妆品股份有限公司 | 用于中药桑白皮的化妆品美白活性物初步筛选方法 |
CN103342687B (zh) * | 2013-07-03 | 2015-02-11 | 江南大学 | 一类具有酪氨酸酶抑制活性的化合物及其制备与应用 |
CN103497091B (zh) * | 2013-09-24 | 2015-06-24 | 江南大学 | 一种具酪氨酸酶抑制活性的化合物及其制备方法 |
CN104829567B (zh) * | 2015-04-10 | 2016-08-17 | 温州泓呈祥科技有限公司 | 茋类化合物,含其的药物组合物及其制备方法和应用 |
CN106749449A (zh) * | 2016-11-15 | 2017-05-31 | 河南中医药大学 | 一种桑辛素M‑6‑O‑β‑D‑葡萄糖苷及其制备方法与应用 |
CN109438213B (zh) * | 2018-10-29 | 2021-12-14 | 中国科学院华南植物园 | 一种异戊烯基查尔酮类化合物及其制备方法 |
CN109369582B (zh) * | 2018-11-01 | 2021-12-10 | 中国科学院华南植物园 | 一种二氢呋喃查尔酮类化合物及其制备方法 |
CN113350243B (zh) * | 2021-07-05 | 2023-05-09 | 贵州中医药大学 | 一种血人参提取物在制备美白祛斑制剂方面的应用 |
CN114569521A (zh) * | 2022-04-20 | 2022-06-03 | 湖南环境生物职业技术学院 | 一种具有乌发黑发作用的提取物及其制备方法与在制备洗发水中的应用 |
-
2011
- 2011-03-13 CN CN 201110059065 patent/CN102153534B/zh not_active Expired - Fee Related
Non-Patent Citations (4)
Title |
---|
Dongho Lee et al..Aromatase Inhibitors from Broussonetia papyrifera.《J. Nat. Prod.》.2001,第64卷(第10期),1286-1293. * |
Shu-Juan Piao et al..New Stilbene, Benzofuran, and Coumarin Glycosides from Morus alba.《Helvetica Chimica Acta》.2009,第92卷(第3期),579–587. * |
Wei-Li Han et al..Three new flavane glucosides from the leaves of Morus wittiorum.《Journal of Asian Natural Products Research》.2010,第12卷(第8期),680–684. * |
姜玉兰 等.桑叶乙酸乙酯萃取物化学成分分析.《延边大学医学学报》.2009,第32卷(第2期),99-101. * |
Also Published As
Publication number | Publication date |
---|---|
CN102153534A (zh) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102153534B (zh) | 具酪氨酸酶抑制活性的化合物及制备方法与用途 | |
CN102924421B (zh) | 一类具酪氨酸酶抑制活性的化合物的制备方法与用途 | |
CN101035548B (zh) | 甾体皂苷药物组合物及其制备方法和应用 | |
CN101711779B (zh) | 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途 | |
CN111087285B (zh) | 一种从铁皮石斛中提取联苄类化合物的方法及其应用 | |
CN102161649B (zh) | 桑叶中提取的多酚类衍生物及制备方法与用途 | |
CN105294623A (zh) | 一种倍半萜内酯类化合物、其制备方法以及应用 | |
CN102180850A (zh) | 一类麦冬中高异黄酮类化合物及制备方法和用途 | |
CN102219782B (zh) | 一种从天然产物中提取分离牡荆素和异牡荆素的方法 | |
CN102161650B (zh) | 桑叶中多酚类次生代谢产物及制备方法与用途 | |
CN103497091B (zh) | 一种具酪氨酸酶抑制活性的化合物及其制备方法 | |
CN102653537B (zh) | 从头花蓼全草中提取制备高纯度水飞蓟宾的方法 | |
CN106565444B (zh) | 山药地上部分菲类化合物的提取方法及应用 | |
CN101721434B (zh) | 一种阿里红有效组分及其制备方法和用途 | |
CN111777657B (zh) | 一种皂苷化合物及其制备方法与应用 | |
CN103372038A (zh) | 积雪草提取物的新应用 | |
CN102125589B (zh) | 一种红参有效组分的制备方法与用途 | |
CN104688798A (zh) | 一种霞草提取物的制备方法及应用 | |
CN103739660A (zh) | 一种化合物、其提取方法、其制备抗肿瘤药物的应用及其制备的抗肿瘤药物 | |
CN104758333B (zh) | 徐长卿c21甾体提取物及其制备方法和用途 | |
CN109748945A (zh) | 四种Gypenoside L和Gypenoside LI乙酰化衍生物及其制备抗肿瘤药物的用途 | |
WO2017139962A1 (zh) | 红景天中提取草质素的方法 | |
CN103417528B (zh) | 一种异巴西红厚壳素的用途 | |
CN111690022B (zh) | 一种从马牙七中分离得到的生物碱及其分离方法和应用 | |
CN102824385A (zh) | 一种楤白皮总皂苷及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130313 |